|
EP3456319A1
|
|
Dpp-4-inhibitor-composition
|
|
EP3456320A1
|
|
Dpp-4-inhibitor-mono-composition
|
|
EP3398590A1
|
|
Orally disintegrating tablet, containing a h1-antihistamine
|
|
EP3335700A1
|
|
Solid pharmaceutical oral dosage form comprising an extended release of the active ingredient comprising mirabegron
|
|
EP3359137A1
|
|
Oral febuxostat tablet
|
|
EP3272336A1
|
|
Atorvastatin composition
|
|
EP3195860A1
|
|
Method for producing an apixaban granulate
|
|
EP3153158A1
|
|
Oral febuxostat tablet
|
|
EP3120837A1
|
|
Ready-to-use solution of bortezomib
|
|
EP3120836A1
|
|
Ready-to-use solution of bortezomib
|
|
DE102012010774A1
|
|
Pharmaceutical pemetrexed solution
|
|
DE102012000786A1
|
|
Process for the preparation of a solid pharmaceutical composition containing the active substance rasagiline
|
|
DE102011108762A1
|
|
A compressed solid pharmaceutical composition comprising amorphous particulate valsartan as an active ingredient
|
|
DE102011103270A1
|
|
Powdered mixture for the preparation of levetiracetam-containing tablets
|
|
DE102010019416A1
|
|
Orodispersible tablet comprising a triptan or an atypical neuroleptic
|
|
DE102010010998A1
|
|
A solid pharmaceutical composition comprising donepezil hydrochloride of crystalline polymorphic form I
|
|
DE102010005124A1
|
|
Solid pharmaceutical composition comprising lercanidipine
|
|
DE102009008186A1
|
|
Solid oral pharmaceutical composition comprising a hydrophobic agent
|
|
DE102009008185A1
|
|
A composition comprising a hydrophobic drug and a phospholipid
|
|
DE102008046995A1
|
|
2-ethoxy-benzoic acid
|
